6 results match your criteria: "Cantonal Hospital of Lucerne and University of Bern[Affiliation]"
Proteomic profiling for biomarker discovery in heparin-induced thrombocytopenia.
Blood Adv
June 2024
Department of Clinical Chemistry, Inselspital University Hospital Bern, Bern, Switzerland.
Article Synopsis
- New analytical techniques allow for the simultaneous assessment of hundreds of proteins, helping to understand their roles in diseases like heparin-induced thrombocytopenia (HIT).
- Researchers used four panels of the Olink proximity extension assay on patients suspected of HIT to identify potential new biomarkers related to thrombus formation, inflammation, and the immune response.
- The study indicated that soluble P-selectin could serve as a significant marker for HIT, with future research planned to evaluate its diagnostic and prognostic value in patient care.
Accuracy of Diagnosing Heparin-Induced Thrombocytopenia.
JAMA Netw Open
March 2024
Department of Clinical Chemistry, Inselspital, Bern University Hospital, Bern, Switzerland.
Importance: Heparin-induced thrombocytopenia (HIT) is a life-threatening condition that requires urgent diagnostic clarification. However, knowledge of the diagnostic utility of the recommended diagnostic tests is limited in clinical practice.
Objective: To evaluate the current diagnostic practice for managing the suspicion of HIT.
A machine-learning model for reducing misdiagnosis in heparin-induced thrombocytopenia: A prospective, multicenter, observational study.
EClinicalMedicine
January 2023
Department of Clinical Chemistry, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Article Synopsis
- Diagnosing heparin-induced thrombocytopenia (HIT) is difficult at the bedside, leading to potential delays in diagnosis or overtreatment, and researchers aimed to improve this using machine-learning algorithms.
- A study with 1393 patients from multiple centers found high accuracy in diagnosing HIT using a machine-learning tool that considered various clinical and lab factors, outperforming the current methods.
- The machine-learning models significantly reduced false-negative and false-positive rates compared to the existing diagnostic algorithm, demonstrating their potential for better clinical outcomes in HIT diagnosis.
Accuracy of a Single, Heparin-Calibrated Anti-Xa Assay for the Measurement of Rivaroxaban, Apixaban, and Edoxaban Drug Concentrations: A Prospective Cross-Sectional Study.
Front Cardiovasc Med
March 2022
Department of Clinical Chemistry, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.
Background: Applying a single anti-Xa assay, calibrated to unfractionated heparin to measure rivaroxaban, apixaban, and edoxaban would simplify laboratory procedures and save healthcare costs.
Aim: We hypothesized that a heparin-calibrated anti-Xa assay would accurately measure rivaroxaban, apixaban, and edoxaban drug concentrations and correctly predict clinically relevant drug levels.
Methods: This analysis is part of the Simple-Xa study, a prospective multicenter cross-sectional study conducted in clinical practice.
Automated Thrombin Generation Assay for Rivaroxaban, Apixaban, and Edoxaban Measurements.
Front Cardiovasc Med
September 2021
Department of Clinical Chemistry, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.
The thrombin generation assay (TG) is a promising approach to measure the degree of anticoagulation in patients treated with direct oral anticoagulants (DOAC). A strong association with plasma drug concentrations would be a meaningful argument for the potential use to monitor DOAC. We aimed to study the correlation of TG with rivaroxaban, apixaban, and edoxaban drug concentrations in a large, prospective multicenter cross-sectional study.
View Article and Find Full Text PDFRecommendations on the use of anticoagulants for the treatment of patients with heparin-induced thrombocytopenia in Switzerland.
Swiss Med Wkly
April 2020
Division of Hematology and Central Hematology Laboratory, Cantonal Hospital of Lucerne and University of Bern, Switzerland.
Heparin-induced thrombocytopenia (HIT) is an immune-mediated adverse drug effect that occurs in 0.1–5% of heparin treated patients. Management of acute HIT currently involves (1) cessation of heparin exposure, and (2) inhibition of coagulation with an anticoagulant other than heparin.
View Article and Find Full Text PDF